US Patent 10196445 Ipilimumab variant with enhanced ADCC
Patent 10196445 was granted and assigned to Bristol-Myers Squibb on February, 2019 by the United States Patent and Trademark Office.
Currently, there are no issues on this topic.
Find more entities like US Patent 10196445 Ipilimumab variant with enhanced ADCC
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
